title: Assessments of serum copper and zinc concentration, and the Cu/Zn ratio determination in patients with multidrug resistant pulmonary tuberculosis (MDR-TB) in Côte d'Ivoire.
abstract: In Côte d'Ivoire, multidrug-resistant tuberculosis (MDR-TB) is a serious public health problem with a prevalence estimated at 2.5% in 2006. Zinc and copper are essential Trace element needed to strengthen the immune system and also useful in the fight against tuberculosis. The Cu / Zn ratio is a good indicator of oxidative stress. The principal aim of this study was to evaluate the serum concentration of some trace element and determine the Cu / Zn ratio in patients with multidrug resistant pulmonary tuberculosis (MDR-TB) before and after second line treatment of TB.
  
  
  
  Blood samples were obtained from 100 MDR-TB patients after confirmation of their status through the microscopic and molecular diagnosis of resistance to Isoniazid and Rifampicin by GeneXpert. The concentration level of zinc and copper were determined using flame air / acetylene atomic absorption spectrometer (AAS) Type Varian Spectr AA-20 Victoria, Australlia.
  
  
  
  A significant decrease in zinc levels (P < 0.05) and an increased Cu / Zn ratio (P < 0.05) was observed in MDR-TB patients compared to controls TB free. During treatment a significant reduction in Cu / Zn ratio (P < 0.05) was observed compared to the initial result.
  
  
  
  The decrease in serum zinc level and the high Cu / Zn ratio could explain the immune system dysfunction and the high level of oxidative stress in patients with MDR-TB. Therefore the evaluation of the zinc and copper status could represent essential parameters in monitoring of TB second line treatment for better treatment management.
authors.affiliation: Department of clinical and Fondamental Biochemistry, Pasteur Institute of Cote d'Ivoire (IPCI), 01 BP 490, Abidjan, 01, Côte d'Ivoire.|Pharmacodynamics Laboratory of Biochemical, University FélixHouphouët- Boigny (UFHB), Abidjan 01 BP V34, Abidjan, 01, Côte d'Ivoire.
authors.forename: Gnogbo Alexis
authors.initials: GA
authors.lastname: Bahi
authors.affiliation: Department of clinical and Fondamental Biochemistry, Pasteur Institute of Cote d'Ivoire (IPCI), 01 BP 490, Abidjan, 01, Côte d'Ivoire.
authors.forename: Lydie
authors.initials: L
authors.lastname: Boyvin
authors.affiliation: Department of clinical and Fondamental Biochemistry, Pasteur Institute of Cote d'Ivoire (IPCI), 01 BP 490, Abidjan, 01, Côte d'Ivoire. Souley_ci@yahoo.fr.
authors.forename: Souleymane
authors.initials: S
authors.lastname: Méité
authors.affiliation: Department of clinical and Fondamental Biochemistry, Pasteur Institute of Cote d'Ivoire (IPCI), 01 BP 490, Abidjan, 01, Côte d'Ivoire.
authors.forename: Gervais Melaine
authors.initials: GM
authors.lastname: M'Boh
authors.affiliation: Department of clinical and Fondamental Biochemistry, Pasteur Institute of Cote d'Ivoire (IPCI), 01 BP 490, Abidjan, 01, Côte d'Ivoire.|Pharmacodynamics Laboratory of Biochemical, University FélixHouphouët- Boigny (UFHB), Abidjan 01 BP V34, Abidjan, 01, Côte d'Ivoire.
authors.forename: Kadjowely
authors.initials: K
authors.lastname: Yeo
authors.affiliation: Department of clinical and Fondamental Biochemistry, Pasteur Institute of Cote d'Ivoire (IPCI), 01 BP 490, Abidjan, 01, Côte d'Ivoire.
authors.forename: Kouassi Raymond
authors.initials: KR
authors.lastname: N'Guessan
authors.affiliation: Pharmacodynamics Laboratory of Biochemical, University FélixHouphouët- Boigny (UFHB), Abidjan 01 BP V34, Abidjan, 01, Côte d'Ivoire.
authors.forename: Alain Dit Philippe
authors.initials: AD
authors.lastname: Bidié
authors.affiliation: Department of clinical and Fondamental Biochemistry, Pasteur Institute of Cote d'Ivoire (IPCI), 01 BP 490, Abidjan, 01, Côte d'Ivoire.|Pharmacodynamics Laboratory of Biochemical, University FélixHouphouët- Boigny (UFHB), Abidjan 01 BP V34, Abidjan, 01, Côte d'Ivoire.
authors.forename: Allico Joseph
authors.initials: AJ
authors.lastname: Djaman
mesh_terms: D000293:Adolescent; D000328:Adult; D000995:Antitubercular Agents / Q000627:therapeutic use; D003300:Copper / Q000097:blood*; D007560:Cote d'Ivoire; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress; D015995:Prevalence; D012293:Rifampin / Q000627:therapeutic use; D014376:Tuberculosis / Q000188:drug therapy; D018088:Tuberculosis, Multidrug-Resistant / Q000097:blood* / Q000188:drug therapy; D014397:Tuberculosis, Pulmonary / Q000097:blood* / Q000188:drug therapy; D014739:Victoria; D055815:Young Adult; D015032:Zinc / Q000097:blood*
chemical_list: D000995:Antitubercular Agents; D003300:Copper; D015032:Zinc; D007538:Isoniazid; D012293:Rifampin
keywords: Abidjan; Cu/Zn Ratio; MDR-TB; Second-line anti-TB drugs; Trace elements